CWK vs MNKD
CWK: Cushman & Wakefield is a leading global commercial real estate services firm providing comprehensive property, facility, and transaction advisory solutions for occupiers and investors. MNKD: MannKind is a biopharmaceutical company specializing in inhaled therapeutic platforms and on-body infusion delivery systems for endocrine and pulmonary conditions.
Side-by-side fundamentals
| Metric | CWK | MNKD | Edge |
|---|---|---|---|
| Price as of 2026-10-30 close | $13.30 | $3.50 | |
| Market cap | $3.1B | $1.1B | |
| P/E as of 2026-10-30 | 44.33 | n/a | |
| Net margin FY2025, SEC XBRL | +0.9% | +1.7% | MNKD higher |
| Operating margin FY2025, SEC XBRL | +4.4% | +11.1% | MNKD higher |
| ROE FY2025, SEC XBRL | +4.5% | n/a | |
| ROA FY2025, SEC XBRL | +1.1% | +0.7% | CWK higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 1.31 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +8.9% | +22.2% | MNKD higher |
| Revenue CAGR (3y) SEC XBRL | +0.6% | +51.8% | MNKD higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.35 | 0.67 | |
| 1-year return as of 2026-10-30 close | -17.8% | -36.9% | CWK higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.